tiprankstipranks
Serina Therapeutics (SER)
NYSE MKT:SER

Serina Therapeutics (SER) Stock Price & Analysis

180 Followers

SER Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$5.93 - $31.19
Previous Close$8.93
Volume8.31K
Average Volume (3M)18.63K
Market Cap
$75.14M
Enterprise Value$79.05M
Total Cash (Recent Filing)$345.00K
Total Debt (Recent Filing)$4.37M
Price to Earnings (P/E)
Beta-0.37
Aug 14, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.06
Shares Outstanding8,413,889
10 Day Avg. Volume26,592
30 Day Avg. Volume18,625
Standard Deviation0.25
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)14.26
Price to Sales (P/S)488.24
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue952.35
Enterprise Value/Gross Profit774.95
Enterprise Value/Ebitda-42.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

SER FAQ

What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was $5.93 and its highest was $31.19 in the past 12 months.
    What is Serina Therapeutics’s market cap?
    Currently, no data Available
    When is Serina Therapeutics’s upcoming earnings report date?
    Serina Therapeutics’s upcoming earnings report date is Aug 14, 2024 which is in 22 days.
      How were Serina Therapeutics’s earnings last quarter?
      Serina Therapeutics released its earnings results on May 14, 2024. The company reported -$3.382 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.382.
        Is Serina Therapeutics overvalued?
        According to Wall Street analysts Serina Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Serina Therapeutics pay dividends?
          Serina Therapeutics does not currently pay dividends.
          What is Serina Therapeutics’s EPS estimate?
          Serina Therapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Serina Therapeutics have?
          Serina Therapeutics has 8,413,889 shares outstanding.
            What happened to Serina Therapeutics’s price movement after its last earnings report?
            Serina Therapeutics reported an EPS of -$3.382 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.437%.
              Which hedge fund is a major shareholder of Serina Therapeutics?
              Among the largest hedge funds holding Serina Therapeutics’s share is Defender Capital, LLC.. It holds Serina Therapeutics’s shares valued at N/A.
                ---

                Serina Therapeutics Stock Smart Score

                Company Description

                Serina Therapeutics

                AgeX Therapeutics, Inc. operates as a biotechnology company. It focuses on the development and commercialization of novel therapeutics targeting human aging. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Arrowhead Pharmaceuticals
                Ardelyx
                Crispr Therapeutics AG
                Sarepta Therapeutics
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis